Detalhe da pesquisa
1.
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma.
Blood
; 141(14): 1685-1690, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36608320
2.
Cereblon enhancer methylation and IMiD resistance in multiple myeloma.
Blood
; 138(18): 1721-1726, 2021 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34115836
3.
Cynaropicrin disrupts tubulin and c-Myc-related signaling and induces parthanatos-type cell death in multiple myeloma.
Acta Pharmacol Sin
; 44(11): 2265-2281, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37344563
4.
The heat shock protein 70 inhibitor VER155008 suppresses the expression of HSP27, HOP and HSP90ß and the androgen receptor, induces apoptosis, and attenuates prostate cancer cell growth.
J Cell Biochem
; 121(1): 407-417, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31222811
5.
RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS.
Haematologica
; 105(9): 2316-2326, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054056
6.
CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
Br J Haematol
; 179(1): 36-49, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28670693
7.
Dioncophyllines C2, D2, and F and Related Naphthylisoquinoline Alkaloids from the Congolese Liana Ancistrocladus ileboensis with Potent Activities against Plasmodium falciparum and against Multiple Myeloma and Leukemia Cell Lines.
J Nat Prod
; 80(2): 443-458, 2017 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28121440
8.
GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.
Haematologica
; 100(3): 377-84, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25637055
9.
PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform.
Br J Haematol
; 166(4): 529-39, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24766330
10.
The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany.
Eur J Cancer
; 207: 114144, 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38852290
11.
The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma.
Br J Haematol
; 160(4): 465-76, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23252346
12.
Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival.
Blood
; 117(6): 1998-2004, 2011 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21149634
13.
The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma.
Haematologica
; 98(7): 1132-41, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23065523
14.
Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy.
Haematologica
; 103(10): e469-e472, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29700168
15.
In Silico, In Vitro, and In Vivo Investigations on Adapalene as Repurposed Third Generation Retinoid against Multiple Myeloma and Leukemia.
Cancers (Basel)
; 15(16)2023 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37627164
16.
[New forms of immunotherapy in uro-oncology : HLA-independent therapeutic approaches with bispecific antibodies and CAR T cells]. / Neue Formen der Immuntherapie für die Uroonkologie : HLA-unabhängige Therapieansätze mit bispezifischen Antikörpern und CAR-T-Zellen.
Urologie
; 62(7): 685-690, 2023 Jul.
Artigo
em Alemão
| MEDLINE | ID: mdl-37341719
17.
Ancistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate.
Pharmaceuticals (Basel)
; 16(8)2023 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37631095
18.
Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.
Br J Haematol
; 159(4): 430-40, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22985491
19.
Disruption of Lipid Raft Microdomains, Regulation of CD38, TP53, and MYC Signaling, and Induction of Apoptosis by Lomitapide in Multiple Myeloma Cells.
Cancer Genomics Proteomics
; 19(5): 540-555, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35985681
20.
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.
Clin Cancer Res
; 28(5): 870-881, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34862243